α-linolenic acid inhibits human renal cell carcinoma cell proliferation through PPAR-γ activation and COX-2 inhibition

LIJUN YANG1*, JIANLIN YUAN1*, LIWEN LIU2, CHANGHONG SHI3, LONGXIN WANG1, FENG TIAN1, FEI LIU1, HE WANG1, CHEN SHAO1, QIANG ZHANG4, ZHINAN CHEN5, WEIJUN QIN1 and WEIHONG WEN5

Departments of 1Urology and 2Ultrasound Diagnosis, Xijing Hospital; 3Laboratory Animals Center, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China; 4Department of Urology, Northwestern University’s Feinberg School of Medicine, Chicago, IL, USA; 5Department of Immunology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China

Received December 8, 2012; Accepted April 30, 2013

DOI: 10.3892/ol.2013.1336

Abstract. ω-3 fatty acids have potential anticancer effects, and consuming food rich in ω-3 fatty acids reduces the human renal cell carcinoma (RCC) risk. However, the direct effect of ω-3 fatty acids on RCC in vitro is unknown. In the present study, the effects of α-linolenic acid (ALA), an ω-3 fatty acid, were observed on cell proliferation in the RCC cell line OS-RC-2. The activity and gene expression levels of peroxisome proliferator-activated receptor-γ (PPAR-γ) and cyclooxygenase-2 (COX-2) in the OS-RC-2 cells were measured by ELISA and real-time RT-PCR, respectively, following ALA treatment. ALA (20-80 µM) dose-dependently suppressed the proliferation of the OS-RC-2 cells. PPAR-γ activity and gene expression were significantly increased by ALA at 20 and 40 µM. COX-2 activity and gene expression levels were significantly decreased by ALA from 20 µM. Use of purely the PPAR-γ agonist, rosiglitazone, decreased the proliferation of the OS-RC-2 cells, while ALA induced further suppression of cell proliferation in the presence of rosiglitazone. The COX-2 inhibitor N-(3-Pyridyl)indomethacinamide induced further suppression of cell proliferation in the presence of rosiglitazone. N-(3-Pyridyl)indomethacinamide also suppressed the proliferation of the OS-RC-2 cells. In the presence of N-(3-Pyridyl)indomethacinamide, ALA and rosiglitazone further inhibited OS-RC-2 cell proliferation. In conclusion, ALA inhibits the cell proliferation of the OS-RC-2 human RCC cell line. PPAR-γ activation and COX-2 inhibition serve as two signaling pathways for the inhibitory effects of ALA on RCC cell proliferation.

Introduction

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults and the most lethal of all genitourinary tumors. Nephrectomy remains the main method of curative treatment for RCC without distant metastasis (1). The other two main types of anticancer treatment in wide clinical use are radiation and chemotherapy. However, the majority of RCCs are resistant to radiation therapy and chemotherapy (2). Current research is focusing on the development of new methods for RCC therapy.

ω-3 fatty acids have potential anticancer effects. The dietary intake of ω-3 fatty acids is associated with a reduced risk of certain types of cancer in human populations and animal models (3). In a large population-based cohort study with data on long-term diet, it was noted that consumption of ocean fish rich in ω-3 fatty acids reduced the RCC risk by ~74% (4,5). In vitro studies have shown that ω-3 fatty acids inhibit cell proliferation and induce apoptosis in certain types of cancer cells (6,7). However, the direct effects of ω-3 fatty acids on RCC in vitro have not been reported.

The anticancer effects of ω-3 fatty acids may be mediated by multiple pathways, including peroxisome proliferator-activated receptor-γ (PPAR-γ) activation. PPAR-γ is a nuclear receptor that regulates lipid homeostasis and is implicated in the pathology of numerous diseases, including obesity and diabetes (8,9). Additionally, studies have demonstrated that PPAR-γ has a significant role in the inhibition of tumor growth, progression and metastasis (10). PPAR-γ is expressed in a number of types of cancer including colon, breast, lung and prostate cancer. PPAR-γ activation inhibits the proliferation of numerous types of cancer cells in vitro. It has been demonstrated that fatty acids are natural ligands of PPAR-γ (11,12). Fatty acids may activate PPAR-γ, then inhibit the growth of cancer cells. However, the role of PPAR-γ in RCC growth has not been clarified.

Cyclooxygenase-2 (COX-2) has also been suggested to be involved in the development of cancers. COX-2 is...
an inducible enzyme involved in inflammatory processes. Increasing evidence indicates that COX-2 inhibition has an important role in the prevention of cancer and in the delay of progression in established cancer. For example, α-3 fatty acids have been shown to downregulate COX-2 expression and inhibit hepatocellular carcinoma cell growth (13). It has been observed that COX-2 is highly expressed in RCC tissues and that it shows a correlation with pathological features and prognosis in patients with RCC (14-16). The role of COX-2 in the development of RCC is not fully understood.

α-linolenic acid (ALA) is an α-3 fatty acid that certain diets are rich in and that may be transformed to other α-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in the cells. In the present study, the effects of ALA on the proliferation of human RCC cell line OS-RC-2 cells were observed in vitro, and the involvement of PPAR-γ and COX-2 was demonstrated in the effects of ALA.

Materials and methods

Cell culture. The human RCC cell line, OS-RC-2, was obtained from ATCC (Rockville, MD, USA). The OS-RC-2 cells were cultured in RPMI-1640 medium (Sigma, St. Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (Sigma). The cells were incubated at 37°C in a 5% CO₂ humidified incubator.

Cell proliferation assay. The cells were seeded into 96-well plates at a density of 10⁴ cells per well. ALA was added into the medium the next day after seeding. Following 48 h of treatment, BrdU was added with ALA into the medium and incubated for one day. The cells were fixed and denatured by incubation with 100 µl FixDenat for 30 min at room temperature. Following the aspiration of FixDenat, the cells were washed with 1 ml blocking buffer [1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS)], then incubated for 90 min with 100 µl anti-BrdU peroxidase-conjugated antibody. The incubation with anti-BrdU peroxidase-conjugated antibody was terminated by three washes with blocking buffer, and 100 µl 3,3′,5,5′-tetramethylbenzidine (TMB) substrates were subsequently added into the wells. Following 5-10 min of incubation with TMB, 25 µl 1 M H₂SO₄ was added to stop the reaction. The absorbance was measured by an enzyme-linked immunosorbent assay (ELISA) reader at a wavelength of 450 nm (Bio-Rad Laboratories, Hercules, CA, USA). The BrdU, antibodies, FixDenat and TMB were provided in the BrdU ELISA kit (Roche, Penzberg, Germany).

PPAR-γ activity assay. The OS-RC-2 cells were seeded into 100-mm dishes and treated with ALA at various doses for 48 h. Subsequent to the treatment, the cells were collected, then centrifuged at 300 x g for 5 min at 4°C. The pellets were washed with ice-cold PBS/phosphatase inhibitor solution, then treated with hypotonic buffer for 15 min. NP-40 was added and the samples were centrifuged for 30 sec at 4°C. The pellets were resuspended in the extraction buffer for 30 min on ice and centrifuged at 14,000 x g for 10 min at 4°C. The supernatants containing the nuclear extracts were collected. The PPAR-γ activity levels of the OS-RC-2 cells were then measured using a PPAR-γ Transcription Factor kit (Cayman, Ann Arbor, MI, USA) according to the manufacturer’s instructions. Briefly, 10 µl nuclear extract from the samples and 90 µl Complete Transcription Factor buffer were added to the designated wells. Following an incubation overnight at 4°C, the wells were washed and the PPAR-γ primary antibodies were added for 1 h at room temperature, followed by washing and incubation with the secondary antibody for a further 1 h at room temperature. The developing solution was added and the reaction was stopped once the blue color had properly developed. The optical density was read with a microplate reader (Bio-Rad Laboratories) at 450 nm.

COX-2 assay. The OS-RC-2 cells were seeded into 100-mm dishes and treated with ALA at various doses for 48 h. Following the treatment, the cells were harvested and centrifuged at 1,000 x g for 10 min at 4°C. The cell pellets were homogenized in cold Tris-HCl buffer and centrifuged at 10,000 x g for 15 min at 4°C. The supernatant was collected for the COX-2 assay. The protein levels of COX-2 were assayed using a human COX-2 assay kit from IBL (Gunma, Japan), which is a solid-phase sandwich ELISA. Briefly, the test samples and diluted standards were added into the appropriate wells and incubated for 1 h at 37°C. Subsequent to washing, the labeled antibody solution was added and incubated for 30 min at 37°C. The developing solution was then added and the reaction was stopped once the blue color had properly developed. The absorbance of each well was read with the plate reader (Bio-Rad Laboratories) at 450 nm.

Statistical analysis. All data are presented as the mean ± SEM. The data were analyzed by one-way ANOVA. P<0.05 was considered to indicate a statistically significant difference for all statistical analyses.

Results

Effects of ALA on human RCC cell line OS-RC-2 cell proliferation. The human RCC OS-RC-2 cells grew well under the
culture conditions. Following 72 h of treatment with ALA at various doses, the cells exhibited a notable suppression of growth. The cell numbers in the groups treated with ALA visibly decreased. To clarify whether the proliferation of the OS-RC-2 cells was affected by ALA, BrdU incorporation into the cells was measured. The results of the BrdU incorporation showed that ALA dose-dependently decreased the incorporation of BrdU into the OS-RC-2 cells, demonstrating an inhibitory action of ALA on OS-RC-2 cell proliferation. The assay values of BrdU incorporation in the 20, 40 and 80 mmol/l ALA treatment groups were 81, 40 and 20% of the control, respectively (Fig. 1).

**Effects of ALA on the activity and expression levels of PPAR-γ and COX-2 in OS-RC-2 cells.** Next, the activity of two factors involved in the regulation of tumor growth, PPAR-γ and COX-2, was investigated. PPAR-γ activity was significantly increased by ALA at 20 and 40 mmol/l compared with the control. However, no significant differences were observed between the 20 and 40 mmol/l ALA groups. Notably, 80 mM ALA did not induce an increase in PPAR-γ activity but rather decreased its activity significantly compared with the control (Fig. 2A). In contrast to the activity of PPAR-γ, COX-2 activity was significantly inhibited in the OS-RC-2 cells by ALA. COX-2 activity, measured using an ELISA kit, dose-dependently decreased in the groups treated with ALA compared with the control group (Fig. 2B).

The gene expression levels of PPAR-γ and COX-2 were also affected by ALA. ALA at 20 and 40 mmol/l induced >60% greater expression of PPAR-γ compared with the control. However, ALA at 80 mmol/l did not increase the expression of PPAR-γ, and instead decreased it to 60% that of the control. By contrast, COX-2 gene expression was significantly suppressed by ALA. ALA at 20, 40 and 80 mmol/l inhibited the expression of COX-2 to 60, 30 and 10% that of the control, respectively (Fig. 3).

**Role of PPAR-γ and COX-2 in ALA-inhibited proliferation of OS-RC-2 cells.** To clarify the role of PPAR-γ and COX-2 in the ALA-inhibited proliferation of the OS-RC-2 cells, the effects of a PPAR-γ agonist on BrdU incorporation into OS-RC-2 cells were observed. Rosiglitazone (10^-5 M), an agonist of PPAR-γ, significantly inhibited BrdU incorporation, supporting the hypothesis that PPAR-γ activation is involved in the inhibition of OS-RC-2 cell proliferation. In combination with PPAR-γ activation by rosiglitazone,
ALA at 40 mmol/l inhibited proliferation, indicating that PPAR-γ activation is not the only pathway in ALA-inhibited proliferation. Moreover, at 10⁻⁵ mol/l, N-(3-Pyridyl)indomethacinamide, a potent and selective COX-2 inhibitor, suppressed the cell proliferation in combination with PPAR-γ activation by rosiglitazone (Fig. 4). Next, the effects of COX-2 inhibition on OS-RC-2 cell proliferation were investigated. N-(3-Pyridyl)indomethacinamide at 10⁻⁴ mol/l suppressed the cell proliferation significantly by ~60% compared with the control. In combination with the COX-2 inhibitor, ALA and the PPAR-γ agonist, rosiglitazone, induced further decreases in proliferation (Fig. 5).

Discussion

The present study demonstrated that ALA, an ω-3 fatty acid, inhibited the proliferation of human RCC cells in vitro, providing direct evidence for the beneficial effect of ω-3 fatty acids on RCC. A previous study showed that ω-3 fatty acids reduce the risk of RCC (5), but no cellular evidence was provided. The present study showed that ALA treatment significantly inhibited RCC cell proliferation by the activation of PPAR-γ and the inhibition of COX-2.

The beneficial effects of ω-3 fatty acids in cancer therapy have been shown in a number of types of cancer. For example, ω-3 fatty acids have been shown to inhibit the growth of breast cancer (18,19) and reduce the risk of lung, prostate and pancreatic cancer (20-23). The present study identified ALA, an ω-3 fatty acid, as an anticancer agent for RCC.

The present study demonstrated that PPAR-γ activation is a signaling pathway that is involved in the action of ALA on OS-RC-2 RCC cells. PPAR-γ is a transcriptional factor that regulates metabolism and numerous other cell functions (24-26). Fatty acids are the natural ligands of PPAR-γ, and ALA is able to activate PPAR-γ (27-29). Therefore, the present study observed the activity of PPAR-γ in OS-RC-2 cells following ALA treatment. As expected, PPAR-γ activity and gene expression were markedly increased by ALA. Furthermore, it was observed that the PPAR-γ agonist inhibited the proliferation of the OS-RC-2 cells. This is supported by studies which reported that the PPAR-γ agonist showed inhibitory effects on cancer growth in certain types of cancers (10,30-32). Taken together, it may be suggested that the activation of PPAR-γ by ALA is one of the signaling pathways for the inhibition of OS-RC-2 cell proliferation.

In combination with the PPAR-γ agonist, ALA further inhibited cell proliferation, indicating that other mechanism besides PPAR-γ were also involved in the action of ALA. The present study clarified that COX-2 inhibition is another mechanism for the inhibition of OS-RC-2 cell proliferation by ALA. COX-2 activity and gene expression were suppressed following ALA treatment. To confirm the role of COX-2 inhibition in the ALA-inhibited proliferation of OS-RC-2 cells, the effects of COX-2 inhibitor on the proliferation of OS-RC-2 cells were investigated. The results showed that the COX-2 inhibitor significantly inhibited OS-RC-2 cell proliferation. Therefore, it was demonstrated that COX-2 inhibition led to decreases in OS-RC-2 cell proliferation. ALA inhibits COX-2 activity, resulting in the inhibition of cell proliferation. Therefore, COX-2 inhibition is considered to be another signaling pathway through which ALA inhibits RCC cell proliferation.

The involvement of COX-2 in cancer cell development has been demonstrated in a number of types of cancer cell (33-35). For example, it has been reported that COX-2 inhibition led to decreases in the proliferation of prostate cancer, MDA-MB-435 cancer and PaCa2 pancreatic cancer cells (36-39). The involvement of COX-2 in RCC has also been suggested. It is reported that COX-2 is highly activated in RCC tissues (16,40,41). The present study demonstrated that COX-2 inhibition suppressed the proliferation of the OS-RC-2 cells, indicating that COX-2...
activation is a factor for RCC cell proliferation. Moreover, the present study showed the inhibition of COX-2 by ALA, an ω-3 fatty acid. This demonstrated the direct correlation between ω-3 fatty acid and COX-2.

Therefore, it is suggested that PPAR-γ activation and COX-2 inhibition serve as two signaling pathways for the inhibitory effects of ALA in RCC cell proliferation, and that these two signaling pathways are parallel in the route map. PPAR-γ activation and COX-2 inhibition have synergistic effects on the inhibition of OS-RC-2 cell proliferation. In the present study, following PPAR-γ activation, the COX-2 inhibitor further suppressed the proliferation of the OS-RC-2 cells in addition to PPAR-γ activation, suggesting that COX-2 is not a downstream molecule of PPAR-γ in OS-RC-2 cells. Although it has been suggested that PPAR-γ regulates COX-2 activity in lung cancer (42,43), the present results did not support the activation of COX-2 by PPAR-γ in the OS-RC-2 cells. The discrepancy between the present and previous studies may be due to tissue-specificity. However, in combination with the COX-2 inhibitor, PPAR-γ induced further inhibition of the cell proliferation, indicating that COX-2 is not the regulator of PPAR-γ action. Therefore, we conclude that PPAR-γ and COX-2 are two parallel signaling pathways that mediate the inhibitory effects of ω-3 fatty acid, ALA, on the proliferation of OS-RC-2 cells.

While ALA increased the activity levels of PPAR-γ at concentrations of 20 and 40 µM in the present study, high doses of ALA up to 80 µM inhibited the activity of PPAR-γ. This inhibition may be due to the inhibition, but not the activation, of PPAR-γ gene expression by ALA at 80 µM. The inhibition of gene expression indicates that high doses of ALA have toxic effects on cell viability. The toxic effects of high doses of ALA on the OS-RC-2 cells were not clearly observable through its inhibition of COX-2 expression as the regulated inhibition and toxic expression overlapped. The inhibition of COX-2 expression by ALA ≤80 mM observed in the present study may not be purely due to the regulated inhibitory effects of ALA: the toxic effects of ALA at high doses may be part of the inhibitory action of ALA. It has been demonstrated that high concentrations of certain fatty acids cause cell death via apoptosis or necrosis in numerous types of cells, such as human melanoma cell lines and pancreatic β-cells (44-46). The loss of membrane integrity and the effects on energy metabolism in cells may be two pathways involved in the toxic action of fatty acids. ALA at high doses may affect integrity or inhibit the energy metabolism of OS-RC-2 cells. The exact mechanism of the toxic action of ALA on OS-RC-2 cells remains to be studied.

In conclusion, the present study demonstrated that an ω-3 fatty acid, ALA, inhibited the proliferation of OS-RC-2 cells, a type of human RCC cell line. PPAR-γ activation and COX-2 inhibition are two signaling pathways involved in the action of ALA on OS-RC-2 cells. We suggest that ALA and drugs regulating the activities of PPAR-γ and COX-2 may be potential targets for RCC therapy.

Acknowledgements

The present study was supported by grants from the National Basic Research Program of China (2009CB521705) and the Natural Scientific Foundation of China (81172420 and 81172146).

References

1. Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med 335: 865-875, 1996.
2. Rini BI, Rathmell WK and Godley P: Renal cell carcinoma. Curr Opin Oncol 20: 300-306, 2008.
3. Rose DP and Connolly JM: Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83: 217-244, 1999.
4. Rashidkhani B, Akesson A, Lindblad P and Wolk A: Major diet patterns and risk of renal cell carcinoma in a prospective cohort of Swedish women. J Nutr 135: 1757-1762, 2005.
5. Wolk A, Larsson SC, Johansson JE and Ekman P: Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA 296: 1371-1376, 2006.
6. Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, Berry D, Steward W and Dennison A: The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur J Cancer 45: 2077-2086, 2009.
7. Wendel M and Heller AR: Anticancer actions of omega-3 fatty acids - current state and future perspectives. Anticancer Agents Med Chem 9: 457-470, 2009.
8. Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 20: 649-688, 1999.
9. Feige JN, Gelman L, Michalik L, Desvergne B and Wahli W: From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45: 123-143, 2006.
10. Krishnan A, Nair SA and Pillar MR: Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med 7: 532-540, 2007.
11. Kliwer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM and Lehrman JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94: 4318-4323, 1997.
12. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sterneck RR, Lehrman JM, Wisely GB, Willson TM, Kliwer SA and Milburn MV: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3: 397-403, 1999.
13. Lim K, Han C, Dai Y, Shen M and Wu T: Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther 8: 3046-3055, 2009.
14. Hashimoto Y, Kon do Y, Kimura G, Matsuzawa I, Sato S, Ishizaki M, Imura N, Akimoto M and Hara S: Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology 44: 353-359, 2004.
15. Khan KN, Stanfield KM, Trajkovic D and Knapp DW: Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 38: 116-119, 2001.
16. Chen Q, Shinhoara N, Abe T, Watanabe T, Nomura K and Koyanagi T: Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 108: 825-832, 2004.
17. Xin X, Yang S, Kowalski J and Gerritsen ME: Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274: 9116-9121, 1999.
18. Rose DP and Connolly JM: Effects of fatty acids and inhibitors of cyclooxygenase synthesis on the growth of a human breast cancer cell line in culture. Cancer Res 50: 7139-7144, 1990.
19. Rose DP, Connolly JM, Rayburn J and Coleman M: Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. J Natl Cancer Inst 87: 587-590, 1995.
20. Karmali RA, Reichel P, Cohen LA, Terano T, Hirai A, Tamura Y and Yoshida S: The effects of dietary omega-3 fatty acids on the du-145 transplantable human prostate tumor. Anticancer Res 7: 1173-1179, 1987.
21. Prentice RL and Sheppard L: Dietary fat and cancer: consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control 1: 81-109, 1990.
22. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Virtamo J and Albanes D: Prospective study of diet and pancreatic cancer in male smokers. Am J Epidemiol 155: 783-792, 2002.

23. Takezaki T, Inoue M, Kataska H, Ikeda S, Yoshida M, Ohashi Y, Tajima K and Tominaga S: Diet and lung cancer risk from a 14-year population-based prospective study in Japan: with special reference to fish consumption. Nutr Cancer 45: 160-167, 2003.

24. Savage DB: PPAR gamma as a metabolic regulator: insights from genomics and pharmacology. Expert Rev Mol Med 7: 1-16, 2005.

25. Knouff C and Auwerx J: Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25: 899-918, 2004.

26. Picard F and Auwerx J: PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22: 167-197, 2002.

27. Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K and Schwabe JW: Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 15: 924-931, 2008.

28. Edwards IJ and O’Flaherty JT: Omega-3 fatty acids and PPARgamma in cancer. PPAR Res 2008: 358052, 2008.

29. Gani OA: Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists? Cardiovasc Diabetol 7: 6, 2008.

30. Gani OA: Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists? Cardiometabolism 15: 365-376, 2009.

31. Roman J: Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy. J Investig Med 56: 528-533, 2008.

32. Voutsadakis IA: Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. J Cancer Res Clin Oncol 133: 917-928, 2007.

33. de Souza Pereira R: Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer. Recent Pat Anticancer Drug Discov 4: 157-163, 2009.

34. Harris RE: Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67, 2009.

35. Fujimura T, Ohta T, Oyama K, Miyashita T and Miwa K: Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer 38: 78-82, 2007.

36. Gilhooly EM and Rose DP: The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 15: 267-270, 1999.

37. Hussain T, Gupta S and Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191: 125-135, 2003.

38. Lee KS, Lee HJ, Ahn KS, Kim SH, Nam D, Kim DK, Choi DY, Ahn KS, Lu J and Kim SH: Cyclooxygenase-2/prostaglandin e2 pathway mediates 9-tetradecanoic induced apoptosis in human PC-3 prostate cancer cells. Cancer Lett 280: 93-100, 2009.

39. Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, Shao Y, Xu HC, Xiao B, Xue YP, Zhou SM, Zhao QS and Ding GX: Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 275: 247-255, 2009.

40. Chêne G, Shinohara N, Abe T, Harabayashi T and Nonomura K: Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line. J Urol 172: 2153-2157, 2004.

41. Andrade LN, de Lima TM, Curi R, Castrucci AM: Toxicity of fatty acids on murine and human melanoma cell lines. Toxicol Lett 152: 109-117, 2004.

42. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE and Nementoff RA: Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 73: 709-717, 2008.

43. Chêne G, Dubourdieu M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, Bernad J, Ariès MF, Charveron M and Pipy B: n-3 polynsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta 1771: 576-589, 2007.

44. Andrade LN, de Lima TM, Curi R, Castrucci AM: Toxicity of fatty acids on murine and human melanoma cell lines. Toxicol In Vitro 19: 553-560, 2005.

45. Azevedo-Martins AK, Monteiro AP, Lima CL, Lenzen S and Curi R: Fatty acid-induced toxicity and neutral lipid accumulation in insulin-producing RINm5F cells. Toxicol In Vitro 20: 1106-1113, 2006.

46. Otton R and Curi R: Toxicity of a mixture of fatty acids on human blood lymphocytes and leukaemia cell lines. Toxicol In Vitro 19: 749-755, 2005.